Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities

Circulating tumor cells (CTCs) have gained importance as an emerging biomarker in solid tumors in the last two decades. Several detection assays have been introduced by various study groups, with EpCAM-based CellSearch system being the most widely used and standardized technique. In breast cancer, d...

Full description

Bibliographic Details
Main Authors: Maggie Banys-Paluchowski, Florian Reinhardt, Tanja Fehm
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Applied Sciences
Subjects:
Online Access:https://www.mdpi.com/2076-3417/10/9/3311
id doaj-69f07aba0a53438aa677fef47094ef0e
record_format Article
spelling doaj-69f07aba0a53438aa677fef47094ef0e2020-11-25T02:11:39ZengMDPI AGApplied Sciences2076-34172020-05-01103311331110.3390/app10093311Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future PossibilitiesMaggie Banys-Paluchowski0Florian Reinhardt1Tanja Fehm2Department of Gynecology, Asklepios Klinik Hamburg-Barmbek, 22307 Hamburg, GermanyDepartment of Obstetrics and Gynecology, University of Düsseldorf, 40225 Düsseldorf, GermanyDepartment of Obstetrics and Gynecology, University of Düsseldorf, 40225 Düsseldorf, GermanyCirculating tumor cells (CTCs) have gained importance as an emerging biomarker in solid tumors in the last two decades. Several detection assays have been introduced by various study groups, with EpCAM-based CellSearch system being the most widely used and standardized technique. In breast cancer, detection of CTCs correlates with clinical outcome in early and metastatic settings. CTC persistence beyond first cycle of palliative chemotherapy indicates poor response to treatment in metastatic situation. Beyond prognostication and therapy monitoring, CTC counts can guide treatment decisions in hormone receptor positive HER2-negative metastatic breast cancer. Furthermore, CTC-based therapy interventions are currently under investigation in clinical trials. In this review, we focus on the current state of knowledge and possible clinical applications of CTC diagnostics in patients with metastatic breast cancer.https://www.mdpi.com/2076-3417/10/9/3311breast cancerliquid biopsycirculating tumor cellsurvivaltargeted therapy
collection DOAJ
language English
format Article
sources DOAJ
author Maggie Banys-Paluchowski
Florian Reinhardt
Tanja Fehm
spellingShingle Maggie Banys-Paluchowski
Florian Reinhardt
Tanja Fehm
Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities
Applied Sciences
breast cancer
liquid biopsy
circulating tumor cell
survival
targeted therapy
author_facet Maggie Banys-Paluchowski
Florian Reinhardt
Tanja Fehm
author_sort Maggie Banys-Paluchowski
title Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities
title_short Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities
title_full Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities
title_fullStr Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities
title_full_unstemmed Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities
title_sort circulating tumor cells in metastatic breast cancer: clinical applications and future possibilities
publisher MDPI AG
series Applied Sciences
issn 2076-3417
publishDate 2020-05-01
description Circulating tumor cells (CTCs) have gained importance as an emerging biomarker in solid tumors in the last two decades. Several detection assays have been introduced by various study groups, with EpCAM-based CellSearch system being the most widely used and standardized technique. In breast cancer, detection of CTCs correlates with clinical outcome in early and metastatic settings. CTC persistence beyond first cycle of palliative chemotherapy indicates poor response to treatment in metastatic situation. Beyond prognostication and therapy monitoring, CTC counts can guide treatment decisions in hormone receptor positive HER2-negative metastatic breast cancer. Furthermore, CTC-based therapy interventions are currently under investigation in clinical trials. In this review, we focus on the current state of knowledge and possible clinical applications of CTC diagnostics in patients with metastatic breast cancer.
topic breast cancer
liquid biopsy
circulating tumor cell
survival
targeted therapy
url https://www.mdpi.com/2076-3417/10/9/3311
work_keys_str_mv AT maggiebanyspaluchowski circulatingtumorcellsinmetastaticbreastcancerclinicalapplicationsandfuturepossibilities
AT florianreinhardt circulatingtumorcellsinmetastaticbreastcancerclinicalapplicationsandfuturepossibilities
AT tanjafehm circulatingtumorcellsinmetastaticbreastcancerclinicalapplicationsandfuturepossibilities
_version_ 1724913481294020608